cerdulatinib Report issue

Small molecule Experimental
AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW
  • Now
Cerdulatinib is a small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies. It has lowest nM IC50 values against TYK2, JAK1, JAK2, JAK3, FMS, and SYK.   Wikipedia

Chemistry

  • SMILES: CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
  • InChIKey: BGLPECHZZQDNCD-UHFFFAOYSA-N
  • Mol. Mass: 445.55
  • ALogP: 1.37
  • ChEMBL Molecules:
    cerdulatinib  
    cerdulatinib  
More Chemistry

Pharmacology

Alternative names

4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide | cerdulatinib | prt062070 | prt-062070 | prt-2070

Organizations (3)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (8)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (8)


 

Hodgkin Disease (Phase 1/Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1/Phase 2)

Lymphoma (Phase 2/Phase 3)

Lymphoma, Follicular (Phase 2/Phase 3)

Lymphoma, Large-Cell, Anaplastic (Phase 2/Phase 3)

Lymphoma, Non-Hodgkin (Phase 1/Phase 2)

Lymphoma, T-Cell (Phase 2/Phase 3)

Vitiligo (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue